SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is trending following news of a strategic manufacturing partnership to scale production of its Intelligent Fingerprinting Drug Screening Reader, ahead of its anticipated U.S. market entry and promising significant operational benefits. The community is actively debating its low float and short squeeze potential, with many discussing whether recent price action is a "stop raid" for further upside or a sign of an impending offering.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to its volatile price action as a low-float SPAC, prompting intense community discussion around its potential for a short squeeze or significant gains. Traders are closely watching its 'tiny float' and high insider ownership, drawing parallels to other recent 'shell company rippers' amidst sharp price swings and trading halts. This speculative interest sees many buying dips and holding, anticipating further explosive moves.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is experiencing extreme volatility, driven by recent CME margin requirement hikes that many in the community view as manipulation to suppress prices. Amid swirling rumors of Chinese export restrictions on silver, traders are sharply divided between anticipating a massive short squeeze from strong physical demand and expecting a significant pullback in the paper market.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is a hot topic, drawing mixed community sentiment regarding its future performance, with many anticipating significant appreciation while others note recent stagnation. Discussions frequently revolve around its foundational role as "digital silver" and the potential for technical indicators to signal a major upward movement. The community is also closely watching broader crypto market trends and Grayscale's influence on LTC's trajectory.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending following a recent FDA approval of NEREUS, its motion-sickness treatment, marking the first new pharmacologic option in decades. The community is actively discussing the drug's potential expansion into the multi-billion dollar GLP-1 nausea market and views VNDA as a prime takeover target, anticipating further catalysts from its robust pipeline including a February FDA decision for Bysanti.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is currently trending on the Cardano ecosystem as its passionate community, known as the "flock," enthusiastically highlights the token's real-world utility through its CockyWingsLLC fried chicken food truck business and a new MemesHub.io DApp. This meme coin is generating buzz for bringing liquidity on-chain and offering passive income opportunities through its liquid staking "Arena," with many anticipating significant growth into 2026.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics ($SNSE) is a hot topic as it undergoes a significant corporate restructuring, including discontinuing its lead drug and exploring strategic alternatives like a sale or merger. The immediate catalyst for community conversation is its exceptionally low share float, which is fueling intense speculation about a potential short squeeze. Traders are actively comparing $SNSE to recent parabolic runners, with many anticipating substantial upward momentum despite the company's fundamental changes.

The Stellar network is an open source, distributed, and community owned network used to facilitate cross-asset transfers of value. Stellar aims to help facilitate cross-asset transfer of value at a fraction of a penny while aiming to be an open financial system that gives people of all income levels access to low-cost financial services. Stellar can handle exchanges between fiat-based currencies and between cryptocurrencies. Stellar.org, the organization that supports Stellar, is centralized like XRP and meant to handle cross platform transactions and micro transactions like XRP. However, unlike Ripple, Stellar.org is non-profit and their platform itself is open source and decentralized.   Stellar was founded by Jed McCaleb in 2014. Jed McCaleb is also the founder of Mt. Gox and co-founder of Ripple, launched the network system Stellar with former lawyer Joyce Kim. Stellar is also a payment technology that aims to connect financial institutions and drastically reduce the cost and time required for cross-border transfers. In fact, both payment networks used the same protocol initially.  Distributed Exchange Through the use of its intermediary currency Lumens (XLM), a user can send any currency that they own to anyone else in a different currency.  For instance, if Joe wanted to send USD to Mary using her EUR, an offer is submitted to the distributed exchange selling USD for EUR. This submitted offer forms is known as an order book. The network will use the order book to find the best exchange rate for the transaction in-order to minimize the fee paid by a user.  This multi-currency transaction is possible because of "Anchors". Anchors are trusted entities that hold people’s deposits and can issue credit. In essence, Anchors serves as the bridge between different currencies and the Stellar network.  Lumens (XLM) Lumens are the native asset (digital currency) that exist on the Stellar network that helps to facilitate multi-currency transactions and prevent spams. For multi-currency transactions, XLM is the digital intermediary that allows for such a transaction to occur at a low cost.  In-order to prevent DoS attacks (aka spams) that would inevitably occur on the Stellar network, a small fee of 0.00001 XLM is associated with every transaction that occurs on the network. This fee is small enough so it does not significantly affect the cost of transaction, but large enough so it dissuades bad actors from spamming the network.   Prior to Protocol 12, Stellar had a built-in inflation mechanism conceived to allow account holders to collectively direct inflation-generated lumens toward projects built on Stellar.  As the network evolved and grew, it became increasingly clear that inflation wasn’t working as intended — account holders either didn’t set their inflation destination or joined inflation pools to claim the inflation themselves, and the operational costs associated with inflation payments continued to rise — and so a protocol change to disable inflation was proposed, implemented, voted on by validators, and ultimately adopted as part of a network upgrade.  The inflation operation is now deprecated. https://developers.stellar.org/docs/glossary/inflation/

Stellar Lumens

Stellar Lumens (XLM) is experiencing renewed interest due to significant institutional developments, including PayPal's stablecoin integration, U.S. Bank's testing of custom stablecoins, and its inclusion in Franklin Templeton's crypto ETF, alongside upcoming network upgrades like Protocol 25. While a segment of the community expresses strong bearish sentiment regarding current price action, others are actively accumulating, bullish on its long-term potential as an ISO 20022 compliant asset. This divergence reflects a battle between immediate price concerns and optimism for XLM's role in the evolving landscape of institutional and cross-border finance.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is highly volatile after the FDA issued a Complete Response Letter for its relacorilant application, seeking additional efficacy evidence despite positive Phase 3 trial data. The market's sharp sell-off is widely viewed by the community as an overreaction, given the company's substantial existing revenue from Korlym, strong cash reserves, and other promising pipeline assets. Investors are now debating the likelihood of a narrower resubmission for relacorilant and the potential for a significant rebound, with many eyeing a temporary bottom.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as the FDA has granted priority review to its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, pointing to an accelerated review timeline. This pivotal development, coupled with strong Auvelity sales and anticipated progress toward an NDA for AXS-12 in narcolepsy, is fueling widespread investor optimism. The community is actively discussing Axsome's "best-in-class" pipeline and commercial execution, anticipating significant long-term value appreciation within the CNS therapeutic landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Revelation Biosciences, Inc. (REVB) on Tuesday announced positive safety and activity data from an early-stage trial of its investigational drug Gemini in stage 3 and 4 chronic kidney disease patients.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.revbiosciences.com/press-releases/revelation-biosciences-announces-groundbreaking-top-line-results-from-prime-clinical-study">trial </a>enrolled 40 patients aged 32 to 78 years. Different patients were treated at four different doses to evaluate the safety of Gemini, Revelation’s formulation of phosphorylated hexaacyl disaccharide, which aims to trigger the innate immune system to release pro-inflammatory cytokines and stimulate immune cell responses. Gemini significantly reduced inflammatory activity in the trial and restored normal cellular response to stimuli, the company said.However, shares of the company tumbled 17% at the time of writing, after the company reported that three severe adverse events were identified at the highest dose of Gemini in the study, including chills, nausea, and vomiting. However, this was all resolved in three hours or less, the company noted, while adding that other reported adverse events were either mild or moderate.On Stocktwits, retail sentiment around <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.revbiosciences.com/press-releases/revelation-biosciences-announces-groundbreaking-top-line-results-from-prime-clinical-study">REVB stock</a> jumped from ‘neutral’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.&nbsp;<figure class="image"><img style="aspect-ratio:623/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_09_at_12_24_31_PM_png_d57363a4a3.webp" alt="REVB's Sentiment Meter and Message Volume as of 12:20 p.m. ET on Sept. 9, 2025 | Source: Stocktwits" width="623" height="61"><figcaption>REVB's Sentiment Meter and Message Volume as of 12:20 p.m. ET on Sept. 9, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user termed the news as “clear bullish” and opined that the stock could explode at any moment.<stembedurl>https://stocktwits.com/hassan101/message/627968361</stembedurl>Another user expressed surprise at the stock drop.<stembedurl>https://stocktwits.com/Chickendinner1/message/627961173</stembedurl>Revelation CEO James Rolke said that the results of the study demonstrate the potential of Gemini to be a “game-changer” in the treatment of acute and chronic inflammation. The company is now looking forward to a meeting with the FDA later this year to discuss the program's advancement, he added.Chronic kidney disease is caused by chronic inflammation. Progression of chronic kidney damage often leads to end-stage renal disease with the need for dialysis or transplantation, the company noted.REVB stock is down by about 89% this year and by about 94% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gary-black-expects-tesla-q3-deliveries-to-exceed-wall-street-estimates-but-sees-full-year-numbers-slip/chwK7ojRdtl">Gary Black Expects Tesla Q3 Deliveries To Exceed Wall Street Estimates But Sees Full-Year Numbers Slip: Retail’s Divided On Stock Performance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Revelation Biosciences Stock Slides 17% After Company Reports 3 Severe Adverse Events In Early Stage Trial Of Inflammation Drug

The firm also reported that Gemini significantly reduced inflammatory activity in the trial and restored normal cellular response to stimuli.

Equity

The firm also reported that Gemini significantly reduced inflammatory activity in the trial and restored normal cellular response to stimuli.


Shares of Revelation Biosciences fell 12.4% in after-hours trading Tuesday after the company said that it would be conducting a 1-for-3 reverse stock split.&nbsp;The split is expected to be effective before the market opens on July 7.&nbsp;Revelation plans to conduct the reverse split to meet Nasdaq's minimum bid requirement.The reverse split, approved at a special shareholder meeting held on June 23, will affect all outstanding shares and adjust related equity instruments, including options, warrants, and restricted stock units (RSUs).&nbsp;Revelation will retain its current ticker symbol “REVB.”Separately, Revelation stated that enrollment is expected to conclude this month in its Phase 1b trial evaluating Gemini in patients with chronic kidney disease.&nbsp;Topline results are expected soon after.Earlier this year, the company said that Gemini reduced inflammation in lab tests involving human immune cells.&nbsp;Cells primed with Gemini showed lower levels of proinflammatory cytokines and higher levels of protective anti-inflammatory markers when exposed to known inflammation triggers, including HMGB-1 and bacterial LPS.&nbsp;The company said that similar effects could be observed in patients, supporting Gemini’s potential in treating inflammation-driven conditions.On Stocktwits, retail sentiment was ‘neutral’ amid ‘low’ message volume.One user described the 1-for-3 reverse split as “small” and suggested that good news could follow shortly.&nbsp;<stembedurl>https://stocktwits.com/SkyLonger/message/619658091</stembedurl>Another user acknowledged the initial panic-driven selloff but argued the situation was different from typical reverse split moves, adding that “bigger news” may be on the way.<stembedurl>https://stocktwits.com/lookgoodplaygood22/message/619658026</stembedurl>Revelation’s stock has declined 92.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Revelation Biosciences Stock Sinks 12% After Reverse Split Reveal; Retail Traders Eye ‘Bigger News’

Shares of Revelation Biosciences fell 12.4% in after-hours trading Tuesday after the company said that it would be conducting a 1-for-3 reverse stock split. 

The company is nearing completion of enrollment in its Phase 1b Gemini trial for CKD, with topline results expected shortly. 

FTSE 100 today: BoE rate decision looms; Vodafone names CFO; Whitbread reports

Investing.com -- British stocks opened lower on Thursday as investors looked ahead to the Bank of England’s rate decision, with markets broadly anticipating no change in interest rates at the meeting.

Frasers Group decides not to make offer for Revolution Beauty

Investing.com -- Frasers Group PLC (LON:FRAS) said on Thursday that it will not make an offer for a U.K.-based cosmetics and skincare retailer   Revolution Beauty Group   PLC (LON:REVB).

Frasers explores potential bid for Revolution Beauty, company confirms

The biotech sector is already buzzing with retail investor interest as the new year begins. Here’s a look at the top three biotech stocks driving conversations on Stocktwits based on message volume jumps on the first trading day of 2025:Carmell Corp (CTCX): +58,100% Message VolumeRegenerative medicine biotech Carmell Corp surged into the spotlight after announcing an acquisition deal with PMGC Holdings’ Elevai Skincare subsidiary. The transaction includes $1.1 million in Carmell stock, $57,000 in cash, and contingent earnouts linked to Elevai’s product sales and revenue milestones.&nbsp;Carmell expects to acquire Elevai’s skincare and haircare portfolio, including a commercial team and inventory with $2.5 million in trailing revenue.&nbsp;Shares rocketed 148% on Thursday but saw some profit-taking early on Friday. Carmell’s stock lost roughly 80% last year.Mustang Bio (MBIO): +27,200% Message VolumeMustang Bio shares climbed 18% on Thursday and gained further in Friday’s pre-market, despite no apparent catalyst.&nbsp;In November, the company secured an extension from Nasdaq to meet compliance requirements and received FDA Orphan Drug Designation for MB-108, an oncolytic virus treatment for malignant glioma.&nbsp;While the stock fell nearly 85% in 2024, recent developments have sparked renewed optimism among investors.Revelation Biosciences (REVB): +9,150% Message VolumeRevelation Biosciences rose 42% on Thursday before sliding in Friday’s pre-market session without any catalyst.&nbsp;Retail buzz centers on its investigational therapy, Gemini, which received FDA clearance last month for a Phase 1b trial targeting chronic kidney disease patients.&nbsp;However, concerns around the company’s cash burn and financing moves have tempered investor enthusiasm. REVB shares dropped over 90% in 2024, leaving the stock a speculative favorite entering 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Carmell, Mustang Bio, Revelation Biosciences Dominate Retail Biotech Talk As 2025 Kicks Off

From acquisition news and FDA designations to fresh optimism for struggling stocks, these biotechs piqued Stocktwits users the most on the first trading day of 2025.

European stock markets slip lower; manufacturing activity data in spotlight

The headline HCOB Spain Manufacturing Purchasing Managers' Index rose to 53.3 in December from 53.1 in November, marking the 11th consecutive month above the 50.0 threshold that indicates growth.

Revolution Beauty settles Chrysalis dispute, shares jump 13% in early trading

Revelation Biosciences Inc. (REVB), a nano-cap biopharmaceutical company, has captured the attention of retail investors in a big way.On Wednesday, REVB saw the highest jump in new retail watchers on Stocktwits, with its following increasing by a staggering 8.79%, as shares doubled in value and became one of the top gainers on U.S. stock exchanges. &nbsp;The surge in interest stems from Revelation's recent success in a Phase 1 clinical trial for Gemini, its proprietary immune preconditioning therapy.The trial confirmed the safety and effectiveness of escalating doses of Gemini, while also showcasing significant, dose-dependent changes in biomarkers indicative of the drug's ability to stimulate the immune system. &nbsp;Encouraged by these results, Revelation CEO James Rolke announced plans to rapidly move forward with a Phase 1b study involving patients later in 2024.Gemini is being developed as a single-dose pre-treatment for two specific purposes: to prevent or reduce the severity of acute kidney injury (AKI) in patients undergoing cardiac surgery; and reduce the incidence, duration, and severity of post-surgical infections.<stembedurl>https://stocktwits.com/Jay_Investor/message/583783850</stembedurl>The positive clinical trial data and the upcoming Phase 1b study have fueled an ‘extremely bullish’ sentiment (89/100) on Stocktwits, with message volume soaring by a remarkable 4,427% over the past 24 hours on Wednesday.<figure class="image"><a href="https://stocktwits.com/symbol/REVB"><img style="aspect-ratio:1320/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/REVB_sentiment_and_message_volume_Aug_22_9c91f8f659.png" alt="REVB sentiment and message volume Aug 22.png" width="1320" height="318"></a><figcaption>REVB sentiment and message volume Aug 22</figcaption></figure>While REVB was among the top gainers in the previous session, it tumbled by 31% on Thursday after the company announced exercising warrants to purchase additional shares at a reduced price.&nbsp;&nbsp;

The surge in interest stems from Revelation's recent success in a Phase 1 clinical trial for Gemini, its proprietary immune preconditioning therapy. 

Revelation Biosciences Stock: Retail Interest Soars After Positive Trial Results

Investor sentiment on Stocktwits is ‘extremely bullish’ due to positive Phase 1 clinical trial results for its immune preconditioning therapy.

Investor sentiment on Stocktwits is ‘extremely bullish’ due to positive Phase 1 clinical trial results for its immune preconditioning therapy. The company is planning a Phase 1b study with patients later in 2024


Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.33	--	--	N/A
Q3 '25	-$1.70	-$1.77	-4.42%	MISSED
Q2 '25	-$16.38	-$7.01	57.20%	BEAT
Q1 '25	-$6.88	-$6.33	7.99%	BEAT
Q4 '24	-$10.32	-$4.98	51.74%	BEAT

REVB
Revelation Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest REVB News

REVBRevelation Biosciences Inc